🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

60,88 USD

Máx. histórico

89,55

116 días

Caída desde máximo

-32,02%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,52%

Cierre anterior

59,97

Rango de hoy

59,16 – 62,16

Volumen hoy

1.334.171

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,93%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,40 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 18 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
06/10/2025 65,00 65,79 64,49 64,80 -0,87% 1,99% 869.000
03/10/2025 63,71 67,40 63,29 65,37 +3,73% 6,45% 2.718.800
02/10/2025 62,03 63,33 61,16 63,02 +1,63% 3,50% 1.177.000
01/10/2025 61,07 62,62 60,80 62,01 +1,04% 2,99% 827.200
30/09/2025 60,89 61,68 60,28 61,37 +1,19% 2,30% 960.300
29/09/2025 59,07 60,94 58,90 60,65 +2,81% 3,46% 1.363.300
26/09/2025 58,38 59,13 57,79 58,99 +1,99% 2,30% 873.900
25/09/2025 59,29 60,14 57,74 57,84 -2,79% 4,04% 1.032.300
24/09/2025 60,14 60,95 58,37 59,50 -1,75% 4,29% 1.173.700
23/09/2025 60,38 61,43 60,38 60,56 -0,48% 1,74% 920.600
22/09/2025 60,00 62,13 59,87 60,85 +0,61% 3,77% 970.000
19/09/2025 62,70 62,99 59,99 60,48 -3,82% 4,78% 1.835.600
18/09/2025 60,55 63,19 59,20 62,88 +3,68% 6,59% 1.140.600
17/09/2025 59,60 61,95 59,60 60,65 +1,61% 3,94% 2.263.000
16/09/2025 58,90 59,81 58,88 59,69 +1,20% 1,58% 1.078.500
15/09/2025 61,45 62,00 58,87 58,98 -3,45% 5,09% 1.300.800
12/09/2025 60,92 62,18 60,48 61,09 +0,21% 2,79% 1.759.200
11/09/2025 58,90 61,11 57,47 60,96 +4,51% 6,19% 1.657.700
10/09/2025 58,14 59,00 57,64 58,33 -0,15% 2,35% 917.300
09/09/2025 57,10 58,66 56,95 58,42 +2,58% 2,99% 1.264.400
08/09/2025 56,88 57,48 56,51 56,95 -0,54% 1,71% 1.400.200
05/09/2025 58,61 58,73 57,08 57,26 -1,29% 2,82% 1.517.100
04/09/2025 55,65 58,05 55,14 58,01 +4,43% 5,22% 1.904.700
03/09/2025 52,88 55,72 52,43 55,55 +5,95% 6,22% 1.758.900
02/09/2025 49,47 53,06 49,38 52,43 +6,28% 7,44% 1.780.500
29/08/2025 49,82 50,53 48,96 49,33 -0,92% 3,15% 906.900
28/08/2025 49,97 50,59 49,65 49,79 +0,02% 1,89% 650.700
27/08/2025 49,35 50,70 48,86 49,78 +0,65% 3,73% 768.900
26/08/2025 49,40 49,67 48,28 49,46 +0,32% 2,82% 784.500
25/08/2025 50,64 51,04 49,20 49,30 -2,51% 3,63% 852.600